Novo Nordisk AS, one of the heavyweight players in the weight loss drug industry, has recently launched a promising new oral GLP-1 drug trial, aiming to further solidify its leading position in this rapidly growing blue ocean market.
The latest trial data released by Novo Nordisk AS reveals that their new oral GLP-1 weight loss drug, amycretin, with a dual-action mechanism to treat obesity, has shown an average weight reduction of 13% in the early 12-week treatment period.
Following this news, the stock price of Novo Nordisk AS listed on the Copenhagen Stock Exchange surged by over 6%.
Although the sample size of the experiment is relatively small, the management of Novo Nordisk AS stated during meetings with investors that this lays a foundation for the further development of oral medications, boosting the company's confidence in the future.
For Novo Nordisk AS, the next generation product line is crucial in maintaining its leading position in the continuously growing market for obesity treatment. The success of Wegovy and its sister drug Ozempic has propelled Novo Nordisk AS to the top spot in the European stock market, with a market value reaching $584 billion.
The company also mentioned that Wegovy effectively reduces the risk of heart attacks and strokes in obese patients, aiding in negotiations with insurance companies.
During the opening speech of the strategic and R&amp;D meeting on that day, CEO Lars Fruergaard Jørgensen stated that the obesity market has &#34;broad prospects.&#34; Camilla Sylvest, the company's head of business strategy and public relations, pointed out that the cost-effectiveness of using Wegovy for patients with heart disease could be twice as high. &#34;This means we are off to a good start in negotiations with payers.&#34;
Despite the monthly pricing of Ozempic and Wegovy exceeding $1000, the demand for Novo Nordisk AS's weight loss drugs has always exceeded supply. The company has begun to expand its production capacity and announced last month a $11 billion acquisition of three pharmaceutical suppliers' factories.
Currently, Novo Nordisk AS faces competition from Zepbound, a GLP-1 drug produced by the American pharmaceutical giant Eli Lilly, while Novo Nordisk AS has monopolized the market for highly effective weight loss injections in the past two years.

The preliminary trial results of the new GLP-1 oral drug are optimistic, leading to a 6% surge in the stock price of Novo Nordisk AS, reaching a historic high.

Novo Nordisk AS's stock price hits a new high as the company releases the latest data on the next-generation weight-loss drug.